T1-T2期乳腺癌且腋窝淋巴结有1-3个转移灶患者乳房切除术后放疗的预后及作用

Prognosis and role of postmastectomy radiotherapy in patients with T1-T2 breast cancer with one to three positive axillary nodes.

作者信息

Chen Z, Hao J, Zhuang H, Yu J

机构信息

Department of Radiotherapy, Tianjin Cancer Institute and Hospital, Tianjin, China.

出版信息

Eur J Gynaecol Oncol. 2011;32(2):141-5.

PMID:21614899

Abstract

PURPOSE

To evaluate the prognosis and role of postmastectomy radiotherapy (PMRT) in T1-T2 breast cancer with one to three positive axillary nodes.

METHODS

The 10-year Kaplan-Meier locoregional recurrence (LRR), distant recurrence (DR), disease-free survival (DFS) and overall survival (OS) were compared between the NO and 1-3N+ cohorts. The role of PMRT was evaluated in the 1-3N+ cohort.

RESULTS

The 10-year LRR, DR, DFS, OS rates in NO and the 1-3N+ cohorts were as follows: LRR 7.5% vs 19.4% (p = 0.011); DR 14.4% vs 23.0% (p = 0.029); DFS 71.3% vs 51.2% (p = 0.001) and OS 77.0% vs 58.7% (p = 0.001). Of the 192 1-3N+ patients not treated and treated with PMRT, the outcomes were: LRR 20.1% vs 18.4% (p = 0.047); DR 26.4% vs 21.5% (p = 0.743); DFS 40.2% vs 55.4% (p = 0.260) and OS 40.7% vs 66.0% (p = 0.344), respectively.

CONCLUSION

PMRT reduces the 10-year LRR rate for such patients, but further examination is needed.

摘要

目的

评估保乳术后放疗（PMRT）在腋窝淋巴结1 - 3个阳性的T1 - T2期乳腺癌中的预后及作用。

方法

比较NO组和1 - 3N +组的10年Kaplan - Meier局部区域复发（LRR）、远处复发（DR）、无病生存率（DFS）和总生存率（OS）。在1 - 3N +组中评估PMRT的作用。

结果

NO组和1 - 3N +组的10年LRR、DR、DFS、OS率如下：LRR分别为7.5%和19.4%（p = 0.011）；DR分别为14.4%和23.0%（p = 0.029）；DFS分别为71.3%和51.2%（p = 0.001）；OS分别为77.0%和58.7%（p = 0.001）。在192例未接受和接受PMRT治疗的1 - 3N +患者中，结果分别为：LRR为20.1%和18.4%（p = 0.047）；DR为26.4%和21.5%（p = 0.743）；DFS为40.2%和55.4%（p = 0.260）；OS为40.7%和66.0%（p = 0.344）。